SPINK2

SPINK2 is a Kazal-type serine protease inhibitor that controls serine protease activity in germ cells and hematopoietic progenitors, with its reactive-site loop dictating target specificity (PMID:19422058, PMID:21705336). Its solution structure is a single Kazal domain stabilized by three disulfide bridges, in which the P1 residue Arg24 is the principal determinant of trypsin-family inhibition, with His25 and Phe26 contributing to binding (PMID:19422058). In the testis SPINK2 is expressed in germ cells from the pachytene spermatocyte stage and is essential for spermatogenesis: its loss elevates serine protease activity and triggers germ cell apoptosis (PMID:21705336), and uncontrolled protease activity in its absence causes Golgi fragmentation, blocks acrosome biogenesis, and produces azoospermia (PMID:28554943). Cell-based rescue established that SPINK2 functions as an acrosin inhibitor that neutralizes protease activity during transit of proteases toward the acrosome (PMID:28554943), with acrosin isoforms confirmed as physiological targets (PMID:31033055). SPAG6 binds SPINK2 and stabilizes its expression and acrosomal localization during spermatogenesis (PMID:32216237). Beyond the germline, SPINK2 secreted by hematopoietic stem and progenitor cells creates a spatially defined zone of serine protease suppression, with PRSS2 and PRSS57 as candidate target proteases (PMID:37378330). SPINK2 also physically interacts with TIG1/RARRES1 to enhance suppression of uPA activity, EMT, and cell invasion (PMID:31886233, PMID:38388961). Its rigid, mutable reactive-site loop makes engineered SPINK2 a scaffold for generating highly selective, picomolar-affinity protease inhibitors, as demonstrated structurally against KLK4 (PMID:31391482).

1. 1991 Medium

   Established that SPINK2 is a secretable, biologically active Kazal inhibitor whose reactive-site loop determines protease specificity, framing the structural basis for its inhibitory function.

   Evidence Recombinant E. coli expression via ompA leader and site-directed mutagenesis of the reactive-site loop with activity assays

   PMID:1801743

   Open questions at the time

   • No physiological substrate identified
   • Endogenous tissue function not addressed
   • No structural model
2. 1993 Medium

   Defined SPINK2 as a single-copy chromosome 4 gene with canonical Kazal exon-intron organization and candidate regulatory elements, providing the genomic foundation.

   Evidence Genomic Southern hybridization, S1 mapping, somatic cell hybrid chromosomal localization

   PMID:8428671

   Open questions at the time

   • Regulatory elements not functionally validated
   • Tissue expression pattern not defined
   • No link to protein function
3. 2009 High

   Resolved the atomic basis of SPINK2 specificity by identifying Arg24 as the P1 specificity determinant within a disulfide-stabilized Kazal fold.

   Evidence NMR solution structure with active-site mutagenesis and trypsin inhibition assays on recombinant protein

   PMID:19422058

   Open questions at the time

   • Physiological in vivo targets not established
   • No cellular or organismal function tested
4. 2011 High

   Demonstrated that SPINK2 is a germ-cell-specific inhibitor essential for spermatogenesis, linking protease control to germ cell survival.

   Evidence Recombinant trypsin-inhibition assay plus gene-trap KO mice with histology, immunoblot and protease activity measurement

   PMID:21705336

   Open questions at the time

   • Specific endogenous protease target not identified
   • Subcellular mechanism of protection not defined
5. 2017 High

   Established the cellular mechanism by which SPINK2 loss causes infertility: failure to neutralize acrosin leads to Golgi fragmentation and acrosome biogenesis failure.

   Evidence Homozygous KO mice with EM, acrosin overexpression rescue in HEK cells, and patient exome sequencing

   PMID:28554943

   Open questions at the time

   • Mechanism of acrosin trafficking control not fully resolved
   • Full spectrum of human mutations not catalogued
6. 2019 Medium

   Identified acrosin isoforms as direct physiological targets, confirming the acrosin-inhibitory mechanism biochemically.

   Evidence Affinity chromatography, mass spectrometry, and kinetic inhibition assays in an avian model

   PMID:31033055

   Open questions at the time

   • Shown in chicken, not human
   • Quantitative inhibition constants for mammalian acrosin not given
7. 2019 Medium

   Revealed a non-germline role: SPINK2 interacts with TIG1/RARRES1 to suppress uPA activity and invasion, expanding its function into protease control in tumor cells.

   Evidence Co-IP in NT2/D1 cells with SPINK2 silencing/overexpression and invasion, migration and uPA activity assays

   PMID:31886233

   Open questions at the time

   • Direct binding not quantified
   • Whether SPINK2 inhibits uPA directly versus via TIG1 unresolved
8. 2019 High

   Showed SPINK2 can be engineered into a tunable scaffold for highly selective protease inhibitors, with structural proof of conformational complementarity.

   Evidence Phage display loop randomization, kinetic KD/Ki measurement, and X-ray crystallography of a KLK4-SPINK2 complex

   PMID:31391482

   Open questions at the time

   • Engineered specificity does not define native target repertoire
   • Therapeutic application not tested in vivo
9. 2019 Medium

   Identified SPAG6 as a binding partner that stabilizes SPINK2 expression and acrosomal localization, linking SPINK2 to the acrosomal protein machinery.

   Evidence Yeast two-hybrid, co-localization in CHO cells, and immunofluorescence in SPAG6-KO mouse testes

   PMID:32216237

   Open questions at the time

   • No reciprocal Co-IP or binding affinity in original report
   • Mechanism of stabilization unknown
10. 2023 Medium

    Extended SPINK2 function to hematopoiesis, showing secreted SPINK2 creates a spatially defined zone of protease suppression around progenitor cells.

    Evidence Localization by flow cytometry/fractionation, degradation kinetics measurement, and target protease expression analysis in primary human HSPCs

    PMID:37378330

    Open questions at the time

    • PRSS2/PRSS57 inhibition only inferred, not biochemically confirmed
    • Functional consequence of the suppression zone untested
11. 2024 Medium

    Confirmed RARRES1-SPINK2 interaction in hepatocellular carcinoma and assigned SPINK2 a tumor-suppressive, drug-sensitizing role.

    Evidence Co-IP with SPINK2 overexpression/knockdown, proliferation/migration assays and in vivo tumor models in HCC

    PMID:38388961

    Open questions at the time

    • Protease-dependence of tumor suppression not established
    • Mechanism of lenvatinib sensitization unknown
12. 2025 Low

    Quantitatively distinguished SPAG6 and SPAG6L binding to SPINK2, refining the acrosomal interaction hierarchy.

    Evidence Binding affinity measurements in compound Spag6/Spag6l knockout mice with ultrastructural analysis (preprint)

    Open questions at the time

    • Preprint with unspecified affinity method
    • Not independently confirmed
13. 2026 Low

    Implicated SPINK2 in malignant self-renewal via a candidate SPINK2-MECOM axis in complex karyotype AML.

    Evidence shRNA knockdown in AML cell lines with proliferation, differentiation and RNA-seq analysis

    PMID:41776172

    Open questions at the time

    • Molecular link between SPINK2 and MECOM not directly established
    • Protease-inhibitory relevance to AML unknown
    • Single-lab cell-line study

• How SPINK2 selects and engages its diverse physiological targets across germline, hematopoietic and tumor contexts, and whether its non-germline roles depend on protease inhibition versus partner-mediated scaffolding, remains unresolved.
• Direct human substrates beyond acrosin not biochemically validated
• Mechanism unifying secreted versus intracellular roles unknown
• Whether tumor and AML phenotypes require inhibitory activity untested